Intravenous nitroglycerin, a drug often found in emergency rooms as a go-to treatment for heart complications, is running short on supply, according to a Medscape report.
Intravenous nitroglycerin was historically produced by three manufacturers: Hospira, Luitpold/American Regent and Baxter. However, Baxter is now the sole manufacturer of the drug for the U.S. markets due to "manufacturing problems" with the other two companies, according to the report.
Baxter has recently reported issues with manufacturing, lessening their supply, according to the report.
"[The U.S. Food and Drug Administration] continues to work with Baxter to address and resolve the shortage and continues to work with Hospira and American Regent as well, since we would like to have all manufacturers back on the market," said Christopher Kelly from the FDA's office of media affairs, in the report.
More Articles on Drug Shortages:
AHA Seeks FDA Action on Saline, IV Solution Shortage
8 Statistics on Care Affected by Drug Shortages
FDA Works to Ease National Saline Shortage